Dr. Lara Discusses Epacadostat in Renal Cell Carcinoma

Primo N. Lara, MD
Published: Wednesday, Jul 19, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma (RCC).

Preliminary results from the phase II ECHO-202/KEYNOTE-037 trial showed encouraging response rates and safety signals with epacadostat plus pembrolizumab (Keytruda) in patients with metastatic RCC.

Lara says the advantages of a drug like epacadostat is that it is oral, so it provides an extra level of convenience, should it become a standard of care in the future.
 


Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma (RCC).

Preliminary results from the phase II ECHO-202/KEYNOTE-037 trial showed encouraging response rates and safety signals with epacadostat plus pembrolizumab (Keytruda) in patients with metastatic RCC.

Lara says the advantages of a drug like epacadostat is that it is oral, so it provides an extra level of convenience, should it become a standard of care in the future.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x